SAN FRANCISCO, CA–(Marketwired – May 12, 2016) – Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International Inc.
(NASDAQ: IPCI) (TSX: I)
has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications.
The Life Sciences Report:
Can you describe Intellipharmaceutics International Inc.’s core technology and how it applies to your abuse-deterrent oxycodone XR new drug application product candidate, which you intend to market as Rexista™ Oxycodone XR?
Domenic Della Penna: Our multidimensional Hypermatrix™ technology is at the core of our controlled-release drug delivery platform. We are applying Hypermatrix™ to a wide range of existing and new extended-release pharmaceuticals. And yes, Hypermatrix™ is at the core of Rexista™, but we are just scratching the surface here on the complexity of Rexista™.
From an abuse deterrence perspective, Rexista™ is designed to be “best in class” within the opioid space, and thus has a number of adjunct technologies beyond Hypermatrix™. The most notable spinoff technology is our “novel Point of Divergence Drug Delivery System,” or “nPODDDS,” which lies at the core of the abuse-deterrence platform supporting Rexista™.
Continue reading this interview: Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse
About Streetwise Reports –
The Life Sciences Report
Investors rely on The Life Sciences Report
to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Intellipharmaceuticals International Inc. paid Streetwise Reports to produce and distribute this interview. Domenic Della Penna had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Penna and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Please see Streetwise Reports’ terms of use and full legal disclaimer.
Jim Patrick
Email contact
